POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for cellular homeostasis, essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a caloric source and may reduce protein catabolism. Sodium chloride 0.45% provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle; sodium and chloride are excreted primarily by the kidneys. |
| Excretion | Potassium: primarily renal (>90%) via distal tubule secretion; minimal fecal. Chloride: renal reabsorption/excretion linked to sodium. Dextrose: metabolized to CO2 and water; <2% renal. Sodium: renal excretion regulated by aldosterone. |
| Half-life | Potassium: terminal half-life approximately 12 hours (3-compartment model), but distribution phase ~1 hour; clinical context: steady-state reached in 2-3 days. |
| Protein binding | Potassium: <5% bound (not significantly protein-bound). Dextrose: no binding. Chloride: minimal binding. |
| Volume of Distribution | Potassium: 0.5-0.7 L/kg (total body water); clinical meaning: reflects distribution primarily in intracellular fluid (98% intracellular). Chloride: 0.2-0.3 L/kg (extracellular fluid). |
| Bioavailability | Intravenous: 100% (complete). Oral: not applicable for this formulation. |
| Onset of Action | Intravenous: immediate for electrolyte effects; dextrose may cause transient insulin release within 5-10 minutes. |
| Duration of Action | Intravenous: electrolyte effects persist as long as infusion continues; post-infusion, potassium redistribution occurs over 1-2 hours; dextrose effects last 1-2 hours. |
| Molecular Weight | 74.55 |
IV infusion at a rate dependent on patient's fluid and electrolyte needs; typical adult maintenance: 1000-2000 mL/day, providing 20-40 mEq potassium per liter.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia; for GFR 30-50 mL/min, reduce dose by 50% and monitor potassium levels closely. |
| Liver impairment | No specific adjustment required for Child-Pugh classification; caution in severe hepatic impairment due to potential for electrolyte disturbances. |
| Pediatric use | 0.5-1 mEq/kg/day IV, not to exceed 3 mEq/kg/day; administered as part of maintenance fluid therapy, adjusted for age and weight; typical rate: 2.5-5 mL/kg/hour. |
| Geriatric use | Start at lower end of adult dosing range; monitor renal function and serum potassium frequently; adjust rate based on renal function and electrolyte balance. |
| 1st trimester | Potassium chloride is generally considered safe in recommended doses for correcting hypokalemia. Use only if clearly needed. |
| 2nd trimester | Same as T1. Monitor serum potassium and renal function. Avoid in patients with impaired renal function. |
| 3rd trimester | Same as T1. Excess potassium can cause maternal and fetal hyperkalemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta by active transport, but fetal serum levels are tightly regulated. Exogenous potassium administration can raise fetal levels if maternal levels are high. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Supplementation in lactating women is considered safe at recommended doses, but monitor maternal potassium levels. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Potassium chloride at physiologic concentrations is not teratogenic. Dextrose and sodium chloride at standard infusion rates do not pose teratogenic risk. Electrolyte imbalances (hyperkalemia, hyperglycemia) could indirectly affect fetal development if severe, but at prescribed doses, risk is negligible. Insufficient data for specific malformation rates. |
| Fetal Monitoring | Monitor maternal serum potassium, glucose, and sodium levels periodically during prolonged infusion. Fetal monitoring indicated if signs of maternal metabolic derangement (e.g., hyperglycemia, hyperkalemia) occur. Assess fluid balance and renal function. |
| Fertility Effects | No known effect on fertility at therapeutic doses. Severe electrolyte disturbances may theoretically impair reproductive function, but no specific evidence. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal failure with oliguria or anuriaAddison's diseaseAcute dehydrationSevere hemolytic reactionsConcomitant use with potassium-sparing diuretics
| Precautions | Use with caution in patients with severe renal impairment, heart failure, or conditions predisposing to hyperkalemia, Monitor serum potassium, sodium, glucose, and fluid balance during prolonged use, Risk of hyperkalemia, especially with rapid or excessive administration, Avoid in patients with anuria or severe renal dysfunction, Solutions containing dextrose may cause hyperglycemia in diabetic patients |
| Food/Dietary | No specific food interactions, but patients on restricted potassium diets (e.g., renal disease) should avoid high-potassium foods (bananas, oranges, potatoes, tomatoes, spinach) while receiving this infusion. For diabetic patients, carbohydrate intake may need adjustment due to dextrose content. |
| Clinical Pearls | Monitor serum potassium and glucose levels frequently during infusion, especially in patients with renal impairment or diabetes. Rate of infusion should not exceed 10 mEq/h for peripheral administration or 20 mEq/h for central line. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics due to risk of hyperkalemia. Solution contains dextrose; avoid in patients with severe hyperglycemia without appropriate insulin coverage. |
| Patient Advice | This intravenous fluid contains potassium, glucose, and sodium to maintain electrolyte balance and hydrate you. · Report any signs of high potassium (muscle weakness, irregular heartbeat, tingling) or high glucose (increased thirst, frequent urination) immediately. · This solution may affect your blood sugar levels; if you have diabetes, your blood glucose will be monitored closely. · Do not adjust the infusion rate yourself; it is controlled by the healthcare team to avoid complications. · Inform your doctor if you are on any medications for high blood pressure or heart failure, as they may increase potassium levels. |
Loading safety data…